Monitor for any subsequent filings that might indicate changes in board dynamics or executive compensation trends, though this specific filing represents standard annual governance procedures.
Price Chart
Executive Summary
PTC Therapeutics is holding its 2026 annual meeting to elect four Class I directors, including Jessica Chutter who was recently appointed to the board. This filing is a definitive proxy statement soliciting shareholder votes on director elections, auditor ratification, and executive compensation. The filing follows a recent 8-K filing announcing Chutter's appointment and other board/executive changes, suggesting these materials are part of an ongoing governance process.
Key Facts
- PTC Therapeutics is holding its 2026 annual meeting to elect four Class I directors: Jessica Chutter, Matthew B. Klein, Stephanie S. Okey, and Jerome B. Zeldis
- The proxy statement solicits votes on three proposals: election of directors, ratification of Ernst & Young as auditors, and approval of executive compensation
- This filing follows a March 25, 2026 Form 8-K announcing Jessica Chutter's appointment to the board and other executive changes
- The filing is routine corporate governance documentation for the annual shareholder meeting
Financial Impact
No direct financial impact - this is a routine governance filing
Risk Factors
- Potential for shareholder activism if there are concerns about board composition or executive pay
- Risk of low shareholder turnout for the vote
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001104659-26-045533 |
| Document: 0001104659-26-045533-index-headers.html | 0001104659-26-045533 |
| Document: 0001104659-26-045533-index.html | 0001104659-26-045533 |
| Document: 0001104659-26-045533.txt | 0001104659-26-045533 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 21, 2026 6w ago | Insider Cluster | $69.82 $65.26 | ▼ −6.53% | ▼ −6.00% | $63.46 (−9.11%) |
Jul 16, 2026 11w ago | Press Release | $78.52 $71.97 | ▲ +8.34% | ▲ +11.96% | $63.46 (+19.18%) |
Jul 16, 2026 11w ago | Insider Cluster | $78.52 $71.97 | ▼ −8.34% | ▼ −11.96% | $63.46 (−19.18%) |
Jul 13, 2026 11w ago | Insider Cluster | $81.33 $74.63 | ▼ −8.24% | ▼ −11.42% | $63.46 (−21.97%) |
Jul 8, 2026 12w ago | Insider Cluster | $88.57 $69.21 | ▼ −21.86% | ▼ −25.13% | $63.46 (−28.35%) |
Jun 26, 2026 14w ago | Insider Cluster | $81.57 $76.82 | ▼ −5.82% | ▼ −5.54% | $63.46 (−22.20%) |
Jun 16, 2026 15w ago | 8-K | $73.27 $78.06 | ▲ +6.54% | ▲ +6.34% | $63.46 (−13.39%) |
Jun 9, 2026 16w ago | 8-K | $73.35 $89.55 | ▲ +22.09% | ▲ +18.46% | $63.46 (−13.48%) |
May 19, 2026 19w ago | Insider Cluster | $71.02 $78.98 | ▲ +11.21% | ▲ +10.47% | $63.46 (−10.64%) |
May 15, 2026 20w ago | Insider Cluster | $70.15 $73.27 | ▲ +4.45% | ▲ +2.87% | $63.46 (−9.54%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access